A rare case of pneumatosis intestinalis after gastrocystostomy in an ovarian cancer patient under bevacizumab treatment

Pneumatosis intestinalis (PI) is a rare condition defined by the presence of air within bowel wall. Several possible etiologies for PI were previously reported. These include any cause of increased intestinal lumen pressure and disruption of bowl mucosa from any mechanical or ischemic causes. The authors report of an ovarian cancer patient that was diagnosed with asymptomatic PI. The patient had several risk factors including bowel surgery, recent gastroscopy and gastrocystostomy, chemotherapy, and finally anti-vascular endothelial growth factor treatment with bevacizumab. The possible etiologies of PI as well as treatment option are discussed.

Pneumatosis intestinalis (PI); Bowel wall; Ovarian cancer; Bevacizumab

[1] Wu L.L., Yang Y.S., Dou Y., Liu Q.S.: “A systematic analysis of pneumatosis cystoids intestinalis”. World J. Gastroenterol., 2013, 19, 4973.

[2] Knechtle S.J., Davidoff A.M., Rice R.P.: “Pneumatosis intestinalis. Surgical management and clinical outcome”. Ann. Surg., 1990, 212, 160.

[3] Khalil P.N., Huber-Wagner S., Ladurner R., Kleespies A., Siebeck M., Mutschler W., et al.: “Natural history, clinical pattern, and surgical considerations of pneumatosis intestinalis”. Eur. J. Med. Res., 2009, 14, 231.

[4] Shinagare A.B., Howard S.A., Krajewski K.M., Zukotynski K.A., Jagannathan J.P., Ramaiya N.H.: “Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management”. AJR Am. J. Roentgenol., 2012, 199, 1259.

[5] Adar T., Paz K.: “Images in clinical medicine. Pneumatosis intesti- nalis”. N. Engl. J. Med., 2013, 368, e19

[6] Tahiri M., Levy J., Alzaid S., Anderson D.: “An approach to pneu- matosis intestinalis: Factors affecting your management”. Int. J. Surg. Case Rep., 2015, 6C, 133.

[7] DuBose J.J., Lissauer M., Maung A.A., Piper G.L., O’Callaghan T.A., Luo-Owen X., et al.: “Pneumatosis Intestinalis Predictive Evaluation Study (PIPES): a multicenter epidemiologic study of the Eastern Association for the Surgery of Trauma”. J. Trauma Acute Care Surg., 2013, 75, 15.

[8] Kameda T., Nakano K., Yamazaki M., Koshimizu T., Morita T.: “Axitinib-induced Pneumatosis Intestinalis and Acute Acalculous Cholecystitis in a Patient with Renal Cell Carcinoma” Urology, 2017, 101, e7.

[9] Coriat R., Ropert S., Mir O., Billemont B., Chaussade S., Massault P.P., et al.: “Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib”. Invest. New Drugs, 2011, 29, 1090.

[10] Asmis T.R., Chung K.Y., Teitcher J.B., Kelsen D.P., Shah M.A.: “Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity”. Invest. New Drugs, 2008, 26, 95.